Kornimate/medical-research-clean huggingface dataset:
alzheimer's prevention through exercise

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to learn about the possible benefits of aerobic exercise in controlling or reducing the amount of amyloid present in the brain, reducing changes in brain structure that may lead to alzheimer's disease (ad), and increasing cognitive ability in individuals that have amyloid deposits and are at risk to develop ad.


Eligibility criteria:
inclusion criteria: * clinical dementia rating 0 (nondemented) * age 65 or older * florbetapir pet evidence of cerebral amyloidosis * sedentary or underactive by the telephone assessment of physical activity * stable doses of medications for 30 days. * clinician judgment regarding subject's health status and likelihood to successfully complete the 1-year exercise intervention exclusion criteria: * clinically significant major psychiatric disorder (e.g., major depressive disorder) according to standard criteria or significant psychiatric symptoms that could impair the completion of the study * clinically-significant systemic illness that may affect safety or completion of the study * history of clinically-evident stroke * clinically-significant infection within the last 30 days * active cardiac condition (e.g. angina, myocardial infarction, atrial fibrillation) or pulmonary condition in the past 2 years that, in the investigator's opinion, could pose a safety risk to the participant-unless cleared for exercise by the participant's primary care physician or cardiologist. * uncontrolled hypertension within the last 6 months * history of cancer in the last 5 years (except non-metastatic basal or squamous cell carcinoma) * history of drug or alcohol abuse as defined by dsm-iv criteria within the last 2 years * insulin-dependent diabetes mellitus * significant pain or musculoskeletal disorder prohibiting participation in an exercise program * unwillingness to undergo or contraindication to brain mri scan. * history within the last 5 years of primary or recurrent malignant disease with the exception of resected localized cutaneous squamous cell carcinoma, basal cell carcinoma, cervical carcinoma, or prostate cancer.

Keywords: alzheimer's disease ad aerobic exercise exercise
salt-fa to increase folate levels

Conditions: Neural Tube Defects; Folic Acid Deficiency; Spina Bifida; Anencephaly-Spina Bifida

Summary: question: how effective is folic acid-fortified iodized salt in increasing serum folate concentrations among non-pregnant and non-lactating women of reproductive age? hypothesis: folic acid-fortified iodized salt can increase serum folate levels and serve as a policy consideration in salt fortification with both iodine and folic acid to reduce serious and fatal birth defects.

salt is an ideal vehicle for fortification because its universal consumption and often centrally processed with established distribution channels. over 70% of households globally have access to iodized salt. considering the success of salt iodization, it is logical to use the existing infrastructure to provide folic acid through this dietary mechanism. aim:to assess increase in blood folate concentrations among women of reproductive age after they consume folic acid-fortified iodized salt. objectives : 1. to examine the effect of consumption of salt fortified with folic acid on serum/plasma folate concentrations among women of reproductive age. 2. to estimate the raise in serum iron, b12 and folate levels after 3 months of study salt consumption.

Eligibility criteria:
inclusion criteria: • willing to voluntarily participate in the study * can comprehend and comply with study requirements * aged between 18 and 45 years. * no documented issues with child bearing potential * resident of the area of study for duration of study. * consume only study salt during study exclusion criteria: * taking multivitamins or fa during study * pregnant or lactating at recruitment or during study * co-morbidities such as malabsorption disorders, severe anemia (hgb \<8.0 g/dl), uncontrolled hypertension, (sbp ≥140 mm hg or dbp ≥90 mm hg), hiv, active tb or malaria infection * history of prior sba delivery * pre-existing medical conditions (i.e., cancer or need for regular medications)
use of positron emission tomography/computed tomography (pet/ct) to assess tumor response to neoadjuvant treatment for distal rectal cancer

Conditions: Rectal Cancer

Summary: preoperative chemoradiation therapy is the preferred initial treatment option for distal rectal cancers. however, assessing tumor response to preoperative chemoradiation therapy remains a challenge to the colorectal surgeon, especially when determining if there is a complete response, observed in more than 10% of cases. the purpose of this study is to evaluate the use of the pet/ct in assessing distal rectal tumor response to preoperative chemoradiation therapy.

patients with distal rectal adenocarcinoma will be submitted to an initial whole body pet/ct prior to the preoperative chemoradiation therapy with 5-fluorouracil and 5040 cgy. six weeks and 12 weeks after the preoperative treatment is finished the pet/ct will be repeated. at 1 and at 2 years after preoperative treatment is concluded another pet/ct will be performed. the colorectal surgeon evaluating the response to chemoradiation therapy will be blinded to the results of the pet/ct, as the radiologist will be blinded to the response assessment. pet/ct results will not be used to determine treatment strategy, unless metastatic disease or other disease is diagnosed. patients with a complete clinical response at 8 weeks will be rigorously followed while patients with an incomplete clinical response at 8 weeks will be submitted to radical surgery. pet/ct results will be compared to current radiological studies and final pathological reports.

Eligibility criteria:
inclusion criteria: * diagnosis of rectal adenocarcinoma * location of tumor less than 7cm from anal verge exclusion criteria: * pregnancy or nursing * metastatic disease (stage iv disease) * previous treatment for any cancer * patients clinically unable to receive neoadjuvant chemoradiotherapy * hypersensitivity to 18fdg

Keywords: rectal cancer positron emission tomography fluorodeoxyglucose f18 computed tomography neoadjuvant therapy chemotherapy radiotherapy
omega tots: a randomized, controlled trial of long-chain polyunsaturated fatty acid supplementation of toddler diets and developmental outcomes

Conditions: Preterm Birth; Child Development

Summary: the purpose of this study is to examine whether supplementation with certain polyunsaturated fatty acids can help the cognitive development of children born preterm.


Eligibility criteria:
inclusion criteria: 1. age 10-16 completed months (age corrected for prematurity) at baseline 2. discontinued regular breastfeeding and formula feeding at the time of randomization 3. gestational age \< 35 completed weeks at birth 4. english is primary language in home 5. informed consent obtained and signed 6. child admitted to any nch managed nicu or children who have ever had a neonatology clinic follow up visit scheduled, regardless of attendance exclusion criteria: 1. feeding problems 2. major malformation, metabolic, or digestive disorder that would preclude participation and/or optimal absorption of the supplement. 3. weight \ 95th percentile for age, per who growth charts 4. consume dha supplement drops, chews, or powders or pediasure, or fatty fish more than 2x per week 5. plans to move out of the area within the next 6 months 6. known corn allergy 7. known soy allergy 8. known fish allergy
relationship of the chinese medical constitution & syndromes in patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: this study is a cross-sectional study. the purpose is to understand the characteristics of chinese medicine constitutional syndrome in patients with polycystic ovary. in addition, the health-related quality of life (sf-36), mental state (stress, depression) of patients with polycystic ovary , anxiety) and the relationship between hormone biochemical indicators and tcm constitutional syndromes, to develop a pioneering study on tcm constitution diagnosis and life guidelines for polycystic ovarian patients and future clinical adjuvant therapy.

the study conducted in the obstetrics and gynecology department of the neihu district of the taipei three military general hospital. it is expected that 200 cases of polycystic ovary will be diagnosed by specialists; "quality of life questionnaire (sf-36)" evaluates the quality of life of patients; "bai and bdi-ii" evaluates patients 'anxiety and depression; "stress perception scale" evaluates patients' life stress and testing the blood indexes of patients such as fsh, lh, e2, testosterone, tsh, prolactine. observe the correlation between the quality of life, psychological state, and blood test values of polycystic ovarian patients with physical characteristics of traditional chinese medicine.

Eligibility criteria:
inclusion criteria: a polycystic ovarian patient was diagnosed by a specialist in obstetrics and gynecology according to the diagnostic criteria set by the rotterdam eshre / asrm-sponsored pcos workshop group (2004) in 2003. exclusion criteria: 1. exclude diseases similar to the clinical manifestations of polycystic ovary, such as cushing syndrome, congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia. 2. diagnose a clear mental disorder (such as schizophrenia, severe depression) or take psychiatric drugs (anti-depression or anxiety drugs). 3. pregnancy, oral contraceptives, use high-dose exogenous androgens, breastfeeding. 4. those with a history of stroke, myocardial infarction, major trauma or surgery within the past six months. 5. have taken chinese medicine in the past month.

Keywords: polycystic ovary syndrome chinese medical constitution & syndromes
sequential versus simultaneous pneumococcal vaccination in elderly: immunological memory and antibody levels

Conditions: Pneumococcal Infections

Summary: the purpose of the present study is to compare the immunological response of pneumococcal serotype specific b-cells, the humoral immune response and safety after sequential vaccination versus simultaneous vaccination with 13-valent pneumococcal conjugate vaccine (pcv13) and 23-valent polysaccharide vaccine (ppv23) versus single vaccination with ppv23 in a prospective, randomized controlled monocentric head-to head clinical study in elderly. the hypothesis of this study is that simultaneous vaccination with pcv13 and ppv23 might achieve an improved immune-response compared to sequential vaccination or single vaccination. adults \>=60 years without previous pneumococcal vaccination will be randomized in three groups and receive either pcv13 on day 0 plus ppv23 6 months later (sequential vaccination) or they receive pcv13 plus ppv23 simultaneous on day 0 (simultaneous vaccination) or they receive ppv23 on day 0 (single vaccination). blood will be taken for pneumococcal serotype-specific b-memory cells against four vaccine-serotypes (st), included in pcv13 and ppv23, vaccine-serotype 3 (st3), vaccine-serotype 14 (st14), vaccine-serotype 19a (st19a) and vaccine-serotype 23f (st23f) at visit 1, 2,4,5,7 and 8 and for antibody levels against the 12 vaccine-serotypes included in pcv13 and ppv23 at visit 1, 3, 4, 6, 7 and 8 in all three groups. adverse events will be recorded for 28 days after each vaccination.


Eligibility criteria:
inclusion criteria: * unvaccinated adults \>= 60 years * written informed consent exclusion criteria: * hypersensitivity against substances included in both vaccines * previous pneumococcal vaccination * pneumonia within the last two months * active infection * autoimmune disease * ongoing or planned immunosuppressive therapy (including corticosteroid treatment with prednisolon equivalent dose \>= 5 mg/d) * active malignant disease * drug abuse or alcoholic abuse * expectation of life \< 2 years * coagulation disorders * burns or injury on the injection site * plegia or paresis of extremity where injection is planned * shock * parallel participation in other clinical trial with intervention * infusion of blood products within the last half year

Keywords: conjugate vaccine polysaccharide vaccine
grn1005 alone or in combination with trastuzumab in breast cancer patients with brain metastases

Conditions: Breast Cancer; Brain Metastases

Summary: the purpose of this study is to assess the efficacy, safety, and tolerability of grn1005 in patients with brain metastases from breast cancer. for patients with her2 positive metastatic breast cancer, grn1005 will be assessed in combination with trastuzumab (herceptin®) as per standard-of-care practice. in addition, this study will evaluate the ability of 18f-flt to determine if the amount of change in the uptake in the brain metastases from breast cancer after grn1005 treatment, correlates with intra-cranial response (for patients enrolled at nci).

please see brief summary section.

Eligibility criteria:
key inclusion criteria: 1. age ≥ 18 years 2. histologically or cytologically-documented breast cancer (her2 status and er/pgr status must be known) 3. brain metastasis from breast cancer with or without prior wbrt 4. at least one radiologically-confirmed and measurable metastatic brain lesion (≥ 1.0 cm in the longest diameter) by gd-mri of the brain \< 14 days prior to first dose (metastatic brain lesions previously treated with srs may not be target or non-target lesions) 5. patients must be neurologically stable: on stable doses of corticosteroids and anticonvulsants (not eiaeds, including phenytoin, phenobarbitol, carbamazepine, fosphenytoin, primidone, oxcarbazepine) for ≥ 5 days prior to obtaining the baseline gd-mri of the brain and ≥ 5 days prior to first dose 6. kps ≥ 70% 7. completed wbrt for intra-cranial lesions ≥ 28 days prior to first dose key exclusion criteria: 1. nci ctcae v4.0 grade ≥ 2 neuropathy 2. cns disease requiring immediate neurosurgical intervention (e.g., resection, shunt placement, etc.) 3. known leptomeningeal disease

Keywords: grn1005 ang1005 peptide-drug conjugate (pdc) lrp-1 targeted therapy breast cancer brain metastases brain tumor blood brain barrier trastuzumab herceptin paclitaxel taxol breast cancer with brain metastases
detect-ip: a clinical decision support system and intelligent procedures to counter some adverse drug events in older hospital patients

Conditions: Patient Acceptance of Health Care; Acute Renal Failure

Summary: current evidence shows that computerized decision support systems (cdss) have shown to be insufficiently effective to prevent adverse drug reactions (adrs) at large scale (e.g. whole hospital). several barriers for successful implementation of cdss have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. the effectiveness of cdss could be increased in two ways. firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent adr in older hospitalized patients). secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. this procedure will reduce over-alerting and prevent task interruption. the hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a cdss, combined with a strategy for managing and transmitting alerts, can reduce specific adrs such as hyperkalemia and acute renal failure.


Eligibility criteria:
inclusion criteria: * hospitalized for 3 days or more in an mco (medicine surgery obstetrics) department participating in the study * patient who gave oral consent to participate in the study * socially insured patient exclusion criteria: * patient discharged or died before d3 of hospitalization * patient in palliative care or end of life on entry to the service * person under legal protection (curatorship) * lack of coverage by the social security system, failure to obtain oral consent to participate in the study

Keywords: acute renal failure hyperkaliemia older people computerized decision support system stepped-wedge
a new risk score for the emergency department in patients with upper gastrointestinal bleeding

Conditions: Upper Gastrointestinal Bleeding (UGIB); Emergency Department Patient; Risk Scores

Summary: abstract background: the aim of this study was to develop a simpler, more practical, and highly effective risk scoring system for patients presenting to the emergency department with upper gastrointestinal bleeding. methods: this single-center retrospective observational study was conducted by reviewing data from patients aged 18 years and older who presented to the emergency medicine clinic of sakarya training and research hospital with symptoms and signs of upper gastrointestinal bleeding between january, 2022 to june, 2023. patients were divided into six groups for analysis. patients included in the transfusion, intervention, intense care unit, readmission or mortality groups were classified as high risk. using the obtained data, a new scoring system was developed, and its effectiveness in predicting high risk and all subgroups was compared with the glasgow blatchford score, aims65, and pre-endoscopic rockall score.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years who presented to the ed with ugib symptoms and signs (hematemesis, melena, and hematochezia) and were hospitalized between january 1, 2022, and june 1, 2023, were included in the study. exclusion criteria: * patients with insufficient data, lower gastrointestinal bleeding, or those who did not undergo endoscopy due to death, refusal of treatment, or symptom resolution were excluded.

Keywords: emergency department upper gastrointestinal bleeding aims65 pre-rs glaskow blatchfor score risk score
the effect of tear supplements on contact lens comfort

Conditions: Dry Eye Syndromes; Meibomian Gland Dysfunction

Summary: the primary goal of this investigation is to determine if lipid based artificial tear supplementation has an impact on contact lens discomfort (cld).

contact lens discomfort (cld) is the most common cause of discontinuing contact lens wear. despite years of research and innovations in technology, cld remains highly prevalent, and thus it is a major concern for patients and practitioners. studies suggest that meibomian gland dysfunction (mgd) is a cause of cld. several lipid-based artificial tears have recently been designed to address dry eye associated with mgd. in this study, the investigators examine if the benefits of lipid based artificial tears extend to improving contact lens comfort. studies have demonstrated some usefulness of non-lipid based tear supplements in the management of contact lens discomfort. however, the relief was moderate and short-term. to date, no study has examined the impact of lipid based artificial tears on contact lens discomfort. in this study, the investigators will address this gap in knowledge.

Eligibility criteria:
inclusion criteria: * patients complaining of contact lens associated discomfort exclusion criteria: * patients who do not have contact lens discomfort; patients who have active inflammation or infection of the anterior segment of the eyes.
increasing effectiveness of an alcohol use reduction exercise using self-talk videos

Conditions: Heavy Drinking

Summary: the goal of the current study is to develop and test an innovative, low-burden method of post-intervention contact that is based on principles of motivational interviewing and the elicitation of change talk. participants will be randomly assigned to an assessment only control group, a standard bmi group or a bmi + video group. participants in the bmi and bmi + video groups will complete a semi-structured, motivational intervention. following the intervention, participants in the bmi + video group will be asked to create a personalized video in which they speak to their future self and describe their reasons for wanting to reduce their alcohol use and their commitment to change. doctoral level psychology graduate students will assist participants in idea generation and creation of the post-intervention video. video group participants will then be sent their personalized videos 21 days after the baseline session, a time when motivation to reduce drinking often begins to wane. it is hypothesized that participants in the bmi + video group will rate the video exercise as helpful, encouraging, and easy to complete. it is further hypothesized that, over the 6-week intervention period, (1) participants in the bmi + video group will reduce their alcohol use more than those in the standard bmi and control groups and (2) participants in the standard bmi group will reduce their alcohol use more than those in the control group.


Eligibility criteria:
inclusion criteria: * meets national institute on alcohol abuse and alcoholism criteria for heavy drinking * 18 year or older * accessibility to internet and laptop with camera and microphone exclusion criteria: * failure to meet inclusion criteria
the drug-drug interaction of shr4640, febuxostat and colchicine in patients with gout

Conditions: Gout

Summary: the objective of the study is to assess the pharmacodynamic properties of drug-drug of shr4640, febuxostat and colchicine interaction in patients with gout.


Eligibility criteria:
inclusion criteria: 1. subject has a body mass index ≥18.5 and ≤30 kg/m2; 2. screening sua value ≥8mg/dl; 3. subject has no clinically relevant abnormalities in vital signs, ecg, physical examination，imaging examination or safety laboratory values. exclusion criteria: 1. subject known or suspected of being sensitive to the study drugs or its ingredient； 2. scr\>uln; 3. history of kidney stones or screening kidney stones by b-ultrasound； 4. history of malignancy within 5 years； 5. history of xanthinuria； 6. donated blood（≥400ml）within 3 months prior to screening or received transfusion of blood。

Keywords: shr4640 febuxostat colchicine pharmacodynamics
detection of lymphnodes using icg during rarp

Conditions: Prostate Cancer

Summary: the purpose of this study is to investigate, whether the detection of lymph nodes by means of intraoperative fluorescence lymphography as part of lymphadenectomy in robot-assisted radical prostatectomy is higher than without the use of indocyanine green (icg).

icg is a fluorescent dye that fluoresces green bound to proteins under illumination in the near-infrared range. using this dye allows to visualize lymphatic nodes, by being injected into the tumor or directly surrounding tissue.

Eligibility criteria:
inclusion criteria: * histologically confirmed locally limited prostate cancer; * intermediate or high risk tumor * recommended and planned prostatectomy; * completed and signed written consent; * voluntarily agreement to participate in this study * age of the study participants ≥ 18 years. exclusion criteria: * allergic reaction to active ingredient (indocyanine green); * iodine allergy; * hyperthyroidism; * high-grade renal impairment; * high-grade hepatic insufficiency; * unwillingness to the storage and disclosure of pseudonymous disease and personal data * psychiatric pre-existing conditions or other circumstances that make a cooperation by the patient in question